Transgene

Transgene Equity Turnover

The Equity Turnover of Transgene (TNG.PA) as of Nov 18, 2026 is 0.40. In the previous year, Equity Turnover was 0.49 — a change of -18.21% (lower).

Equity Turnover

0.40

YoY

-18.21%

Last updated:

Equity Turnover of Transgene is 2024 0.40 . Equity Turnover of Transgene was 2023 0.49 . It decreases by -18.21% lower compared to the previous year.

The Transgene Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2017
0.27 EUR
Jan 1, 2018
0.19 EUR
Jan 1, 2019
0.20 EUR
Jan 1, 2020
0.19 EUR
Jan 1, 2021
0.25 EUR
Jan 1, 2022
0.26 EUR
Jan 1, 2023
0.49 EUR
Jan 1, 2024
0.40 EUR
The Transgene Equity Turnover history
YEAREquity TurnoverYoY
0.40-18.21%
0.49+85.00%
0.26+4.41%
0.25+36.15%
0.19-8.13%
0.20+4.85%
0.19-27.29%
0.27+41.45%
0.19-47.91%
0.36+133.21%
0.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Equity Turnover of Transgene is 0.40 in 2024.

Equity Turnover of Transgene changed from 0.49 to 0.40, representing a -18.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Transgene since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Transgene

All Key Metrics — Transgene